Johnson & Johnson agreed on 8 June to acquire Firefly Bio, a South San Francisco developer of degrader antibody conjugates, for $1bn in cash.
Why Johnson & Johnson is buying Firefly Bio, Inc.
J&J said the Firelink platform broadens its ability to target pan-KRAS and other drivers of hard-to-treat cancers, delivering highly selective protein degraders to tumour cells while sparing healthy cells.
“We believe the proprietary Firelink™ platform will overcome the limitations of current treatments.”
Deal terms and financing
The all-cash deal adds preclinical candidates across several solid tumour types. J&J said it would disclose the accounting treatment on or before closing.
Regulatory approvals and timing
Closing was subject to regulatory approvals. J&J announced on 29 July 2026 that it had completed the acquisition.
Market context
Firefly emerged in February 2024 with m of funding from investors including Versant Ventures and Eli Lilly, DCAT Value Chain Insights reported. J&J's Reed noted that KRAS has long been considered an undruggable target.
